血府逐瘀丸对动脉粥样硬化血瘀征象及危险因素影响的研究

作者	单位
李艳梅	Li Yanmei, Chen Keji, Shi Zaixiang, et al (Xiyuan Hospital China Academg of TCM, Beijing (100091
陈可冀	Li Yanmei, Chen Keji, Shi Zaixiang, et al (Xiyuan Hospital China Academg of TCM, Beijing (100091
史载祥	Li Yanmei, Chen Keji, Shi Zaixiang, et al (Xiyuan Hospital China Academg of TCM, Beijing (100091
张铁忠	Li Yanmei, Chen Keji, Shi Zaixiang, et al (Xiyuan Hospital China Academg of TCM, Beijing (100091

摘要点击次数: 1943

全文下载次数: 963

中文摘要:

观察血府逐瘀丸对动脉粥样硬化血瘀征象和危险因素的影响。方法：将５７例患者随机分为血府逐瘀丸组（３０例）和阿斯匹林组（２７例），分别给予血府逐瘀丸口服，每次６ｇ，每日３次。小剂量阿斯匹林每次４０ｍｇ，每日１次，治疗１个月。结果：血府逐瘀丸能够改善动脉粥样硬化患者的血瘀证候（Ｐ＜０．０１），降低体内动脉粥样硬化危险因素──高血胆固醇（Ｐ＜０．０５）、氧化低密度脂蛋白（Ｐ＜０．０５）和血浆内。颗粒膜蛋白水平（Ｐ＜０．０１）。结论：血府逐瘀丸对延缓动脉粥样硬化有一定积极作用。

英文摘要:

To observe the effect of Xuefuzhuyu Pill (XFZYP) on blood stasis syndrome and risk factor of atherosclerosis. Methods: Fifty-seven patients of atherosclerosis were randomly divided into XFZYP group (30 cases) and aspirin group (27 cases) treated with XFZYP (6g, three times daily) and aspirin (40mg per day) oral taken respectively for one month. Results: XFZYP could improve blood stasis syndrome of patients (P<0.01) and reduced the level of risk factor of atherosclerosis, including high blood cholesterol (P<0.01), oxidation of low density lipoprotein (P<0.05) and plasma granule membrane protein Q (P<0.01). Conclusion: XFZYP is beneficial to retard the progress of atherosclerosis.

关闭